PHYSIOSOL PH 7.4 IN PLASTIC CONTAINER
Clinical safety rating: caution
Comprehensive clinical and safety monograph for PHYSIOSOL PH 7.4 IN PLASTIC CONTAINER (PHYSIOSOL PH 7.4 IN PLASTIC CONTAINER).
Replacement of extracellular fluid and electrolytes; provides buffering capacity via bicarbonate precursor (acetate) and maintains physiological pH.
| Metabolism | Acetate is metabolized primarily in the liver and muscles to bicarbonate. |
| Excretion | Primarily renal; >95% of infused ions (sodium, chloride, lactate, calcium, magnesium) are excreted unchanged in urine. Biliary/fecal elimination negligible (<1%). |
| Half-life | Not applicable; components follow first-order kinetics with rapid redistribution. Lactate half-life ~15-30 minutes (hepatic metabolism). |
| Protein binding | Negligible (<1%); ions are free in plasma (no significant protein binding). |
| Volume of Distribution | 0.4 L/kg; distributes mainly in extracellular fluid (ECF). |
| Bioavailability | 100% (intravenous); not absorbed orally. |
| Onset of Action | Immediate upon intravenous infusion; correction of hypovolemia occurs within minutes. |
| Duration of Action | Short; effects last ~1-2 hours post-infusion due to rapid renal excretion and redistribution. |
Intravenous infusion, rate adjusted based on clinical status and electrolyte needs; typical adult dose is 500-1000 mL over 1-2 hours.
| Dosage form | SOLUTION |
| Renal impairment | Contraindicated in oliguric or anuric renal failure; in GFR <30 mL/min, avoid use or monitor electrolytes closely; no specific GFR-based dose adjustment. |
| Liver impairment | No specific Child-Pugh based adjustments; use with caution in hepatic impairment due to risk of fluid overload. |
| Pediatric use | Weight-based dosing: 5-10 mL/kg intravenous infusion over 1-2 hours, not to exceed 30 mL/kg/day. |
| Geriatric use | Use with caution due to increased risk of fluid overload and electrolyte imbalance; adjust rate and volume based on renal function and comorbidities, typical initial dose 500 mL over 2-3 hours. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for PHYSIOSOL PH 7.4 IN PLASTIC CONTAINER (PHYSIOSOL PH 7.4 IN PLASTIC CONTAINER).
| Breastfeeding | Physiosol pH 7.4 is compatible with breastfeeding. No M/P ratio is available; however, components are normal plasma constituents and unlikely to be excreted into breast milk in clinically significant amounts. |
| Teratogenic Risk | Physiosol pH 7.4 (balanced electrolyte solution) is considered low risk for teratogenicity. There are no known fetal risks associated with its use in any trimester, as it is a physiological solution. However, large volumes or rapid administration could theoretically cause maternal electrolyte imbalances, which may indirectly affect the fetus. |
■ FDA Black Box Warning
None.
| Serious Effects |
["Hypersensitivity to any component","Severe hypernatremia or severe hyperchloremia","Severe metabolic alkalosis","Patients with contraindications to intravenous fluid administration"]
| Precautions | ["Use with caution in patients with severe renal impairment, heart failure, or conditions associated with sodium retention","Monitor serum electrolytes, fluid balance, and acid-base status during prolonged administration","Risk of volume overload in patients with compromised cardiac or renal function","Contains aluminum; may be toxic with prolonged use in patients with renal impairment"] |
Loading safety data…
| Fetal Monitoring | Monitor maternal serum electrolytes, fluid balance, and renal function during prolonged or high-volume administration. In pregnancy, monitor for signs of fluid overload or electrolyte disturbances due to increased plasma volume. |
| Fertility Effects | No known adverse effects on fertility. The solution contains standard electrolytes and water, which are not expected to impair reproductive function. |